Every 10-Q that InfuSystem Holdings, Inc. (INFU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INFU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INFU filings page.
InfuSystem Holdings reported Q2 2026 net revenues of $36,933 (in thousands), up 2.6% from $36,002 (in thousands), as gross margin increased to 58.0%. Net income for the quarter rose to $3,231 (in thousands), or $0.15 diluted EPS, compared with $2,599 (in thousands), or $0.12. For the first half of 2026, net revenues were $70,617 (in thousands) and net income was $4,248 (in thousands), versus $70,718 and $2,332 (in thousands) a year earlier.
Patient Services revenue grew 15.2% in Q2, driven by higher Oncology volume and 154% growth in Wound Care, including new compression therapy products, while Device Solutions revenue declined 16.1% following a restructured GE Healthcare services contract and a prior-period rental buyout. Total assets were $97,700 (in thousands) with long‑term debt of $20,424 (in thousands) and available liquidity of $55,207 (in thousands). Operating cash flow was $7,747 (in thousands) for the first half, supporting continued investment in medical equipment and IT, and the board authorized a new $20,000 (in thousands) share repurchase program through June 30, 2028.
InfuSystem Holdings reported Q1 2026 net revenue of $33.7 million, down 3% from $34.7 million a year earlier, but moved to net income of $1.0 million versus a $0.3 million loss. Gross margin improved to 58.4% from 55.2% as higher-margin Patient Services outpaced softer Device Solutions.
Patient Services revenue rose 6.4% to $22.1 million, driven by oncology and fast-growing wound care, while Device Solutions fell 16.9% to $11.6 million amid lower biomedical services and prior-year rental buyout effects. Operating income more than doubled to $1.6 million. Cash was $2.1 million with $20.0 million drawn on a $75.0 million revolver and $55.0 million of remaining availability. The company continued its share repurchase program, having bought back $11.8 million of stock cumulatively.
InfuSystem Holdings (INFU) reported higher Q3 results. Net revenues were $36,488k, up from $35,320k. Gross profit rose to $20,820k and operating income reached $3,811k. Net income was $2,259k, or $0.11 per diluted share, compared with $1,807k, or $0.08 per share, a year ago.
For the first nine months, net revenues were $107,206k versus $101,013k, with net income of $4,591k ($0.22 diluted). Cash provided by operating activities was $17,282k, reflecting stronger cash generation. The company repurchased $8,563k of common stock year-to-date under its $20,000k authorization.
Segment mix in Q3 showed Patient Services external revenue of $22,363k and Device Solutions external revenue of $14,125k. InfuSystem acquired certain assets of Apollo Medical Supply for $1,412k to expand wound care within Patient Services. The revolving credit facility had $21,360k outstanding and $53,640k available, with maturity extended to July 15, 2030.